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Supplementary Methods 
 
Participants and Setting 
Inclusion criteria 
The participant had to meet EACH of the following criteria: 
1) A clinical syndrome comprising any of the following:  
  a) localised pain, OR  
  b) localised erythema, OR  
  c) temperature >38.0ºC, OR  
  d) a discharging sinus or wound  
2) Willing and able to give informed consent 
3) Aged 18 years or above 
4) Had received 7 days or less of intravenous therapy after an appropriate 
surgical intervention to treat bone or joint infection (regardless of pre-surgical 
antibiotics) or, if no surgical intervention was required, the patient had received 
7 days or less of intravenous therapy after the start of planned curative 
treatment for the relevant clinical episode  
5) Life expectancy > 1 year 
6) Acute or chronic bone or joint infection in one of the following categories:  
 a) 1native osteomyelitis (i.e., bone infection without metalwork)  
           including haematogenous or contiguous osteomyelitis 
 b) 2native joint sepsis treated by excision arthroplasty;  
 c) prosthetic joint infection treated by debridement and retention,  
 by one stage revision or by excision of the prosthetic joint (with or  
 without planned re- implantation);  
 d) 3orthopedic fixation device treated by debridement and retention, or 
 by debridement and removal;  
 e) 4spinal infection  
 
1 
This group consisted of osteomyelitis of the extra-axial skeleton only; vertebral 
osteomyelitis was categorized separately under (e).     
 
2 
Patients with native joint sepsis without associated osteomyelitis were not eligible as 
they would not ordinarily require at least six weeks of IV antibiotic therapy or excision 
arthroplasty. 
 
3 
All participants in this group had a fixation device associated infection; prosthetic 
joints were categorized separately under (c)   
 
4 
All participants in this group had vertebral osteomyelitis with or without associated 
discitis or soft tissue infection.    
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Exclusion criteria 
The participant was ineligible if he or she met ANY one of the following criteria: 
 
1) Staphylococcus aureus bacteraemia on presentation or within the previous 
month 
2) Bacterial endocarditis, either on presentation or within the previous month 
(NB: there were no study mandated investigations, so participants were not 
required to have echocardiograms, blood cultures, or any other investigations 
to exclude endocarditis in the absence of a clinical indication)  
3) Any other concomitant infection which, in the opinion of the clinician 
responsible for the patient, required a prolonged course of intravenous 
antibiotic therapy (e.g., mediastinal infection or central nervous system 
infection)  
4) Mild osteomyelitis, defined as bone infection which, in the opinion of the 
infection specialist responsible, required less than six weeks of antibiotic 
therapy 
5) An infection for which there were no suitable antibiotic choices to permit 
randomization between the two arms of the trial (for example, where 
organisms were only sensitive to intravenous antibiotics)  
6) Prior enrolment in the trial  
7) Septic shock or systemic features requiring intravenous antibiotic therapy in 
the opinion of the treating clinician (the patient could be re-evaluated if these 
features resolved within seven days of the start of treatment episode)  
8) Unlikely to comply with trial requirements following randomization in the 
opinion of the investigator  
9) Clinical, histological or microbiological evidence of mycobacterial, fungal, 
parasitic or viral aetiology of the infection 
10) Receiving an investigational medical product as part of another clinical trial 
 
The use of antibiotic-loaded cement in spacers, bone substitutes or beads at the site 
of infection was not an exclusion criterion, but was recorded. Pregnancy, renal failure 
and liver failure were not exclusion criteria, provided that suitable antibiotic options 
could be identified for both IV and PO therapy prior to randomization. 
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Diagnostic certainty at trial entry 
Baseline data for each participant were assessed for certainty of diagnosis of bone or 
joint infection based on the following criteria that were predefined in the protocol. 
 
Definite evidence of infection at baseline was defined by one or more of the following: 
a) isolating bacteria from 2 or more samples of bone/peri-prosthetic tissue, 
where the bacteria isolated from these samples were indistinguishable 
according to routine laboratory tests, including the antibiogram 
b) a pathogenic organism (e.g. Staphylococcus aureus but not 
Staphylococcus epidermidis) on a single, closed, biopsy of native bone or peri-
prosthetic tissue 
c) diagnostic histology on bone/peri-prosthetic tissue 
d) a draining sinus tract arising from bone/prosthesis or  
e) frank pus adjacent to bone/ prosthesis 
If any of these criteria were met, then the category “definitive” infection was applied 
without blinded, independent review. 
Where these criteria were not met, three independent clinicians, uninvolved in 
recruitment or management of participants, were sent a redacted copy of the 
patient’s admission notes and laboratory results from the time of randomisation, and 
asked to apply the following criteria to determine “probable” or “possible” infection: 
Infection was categorized as “probable” where microbiological sampling had not been 
undertaken, AND none of the other criteria for definite infection had been fulfilled 
AND any one of the following were met:  
a) Radiological or operative findings of periosteal changes suggesting chronic 
osteomyelitis OR 
b) Radiological findings suggesting vertebral infection OR 
c) The development of a discharging wound after an orthopaedic procedure 
where prosthetic material had been implanted OR 
d) The presence of deep pus close to but not adjacent to bone/prosthetic 
joint/orthopaedic device OR 
e) The presence of peri-prosthetic necrotic bone OR 
f) Rapid loosening of a joint prosthesis/orthopaedic device (i.e. leading to 
localized pain in less than 3 months since implantation) in the absence of a 
mechanical explanation for rapid loosening. 
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Infection was categorized as “possible” where microbiological sampling had been 
undertaken with negative results (according to criteria described above for “definite” 
infection) AND other criteria for definite infection were not fulfilled AND in addition 
one or more of the criteria listed a) to f) above was met. 
 
Where the review committee members differed in their initial categorization of a 
participant, consensus was achieved by discussion or, if necessary, by majority 
opinion. 
 
Interventions 
Participants were required to start their randomized treatment strategy within seven 
days of the start of the treatment episode which, in most cases was defined by the 
date of surgical intervention; this was to allow sufficient time for availability of 
microbiological culture results and for recovery from surgery and anaesthesia.  Prior 
to randomization, the choice of agents were a patient to be randomized to each arm 
was determined by a specialist in clinical infection based on clinically relevant 
variables including antimicrobial susceptibility, drug interactions, comorbidities, drug 
allergies, prior infections and local epidemiology; patients were ineligible if no 
suitable oral option could be identified. It is therefore likely that the most appropriate 
antibiotic regime, individualized for each participant, would have been selected 
according to criteria similar to those used in routine daily practice outside the context 
of a clinical trial. As antibiotic susceptibility informed part of the eligibility criteria 
(specifically, an exclusion criteria was ‘no treatment options available for either PO or 
IV therapy at the point of randomization’), we did not routinely collect data on 
adequacy of antimicrobial therapy on the case record forms.  
 
Participants randomized to PO therapy were permitted up to five days of IV antibiotic 
therapy for intercurrent infections unrelated to the incident orthopaedic infection 
without meeting an endpoint or deviating from the protocol.  Participants randomized 
to IV therapy were permitted adjunctive oral therapy, such as oral rifampicin, in order 
to reflect standard practice outside the context of a clinical trial. The infection 
specialist was permitted to alter the choice of antibiotic agent according to clinical 
need (e.g. due to side effects or emerging laboratory results). If suitable alternatives 
were available within the allocated strategy, the patient remained within protocol. If 
no alternative antibiotic agent was available within the randomized strategy, an early 
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exit from strategy (secondary endpoint) was recorded but the participant continued 
follow-up according to the trial protocol and was included in the ‘intention to treat’ 
analysis. 
 
Assessments  
Trial specific data were obtained either from direct face-to-face participant contact at 
predefined time points, or from their clinical case records provided that their routine 
clinical review occurred within a specified range: for day 42 (range 21 to 63), day 120 
(range 70 to 180) and day 365 (range 250 to 420). If insufficient data were available 
from the clinical care record, the investigator arranged a telephone review with the 
participant or their general practitioner. 
 
Study oversight 
The study was conceived by Philip Bejon and designed by physicians and surgeons 
at the Oxford Bone Infection Unit. Data were collected by the investigators and 
associated site personnel, analysed by Ines Rombach and Sarah Walker and 
interpreted by the authors. The first, second and last author wrote the first draft of the 
manuscript. All authors participated in review and editing of the manuscript, approved 
the submitted version and vouch for its accuracy.   
 
Endpoint definitions 
Potential primary endpoints were identified through post-randomization prospective 
surveillance, and reviewed by an endpoint committee blind to the treatment group.  
Potential endpoints were identified and notified to the end-point committee according 
to the following protocol definition: ‘Any post-randomization re-admission or return to 
theatre with signs or symptoms at the anatomical site of infection will be considered a 
potential endpoint. In addition, any signs or symptoms identified on review of the 
patient or their hospital notes at follow up visits that, in the opinion of the study 
clinician, may represent treatment failure will be considered a potential endpoint.’    
 
The primary endpoint was:  failure of infection treatment, where definite failure was 
indicated by one or more of the following: 
a) isolating bacteria from 2 or more samples of bone/peri-prosthetic tissue, 
where the bacteria isolated from these samples were indistinguishable 
according to routine laboratory tests, including the antibiogram. 
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b) a pathogenic organism (e.g. Staphylococcus aureus but not 
Staphylococcus epidermidis) on a single, closed, biopsy of native bone or peri-
prosthetic tissue 
c) diagnostic histology on bone/peri-prosthetic tissue 
d) a draining sinus tract arising from bone/prosthesis or  
e) frank pus adjacent to bone/ prosthesis. 
 
Secondary endpoints were: 
1) SAEs, including death (i.e. all cause) according to treatment allocation; 
2) Line complications (i.e. infection, thrombosis or other events requiring early 
removal or replacement of the line); 
3) “Probable” or “possible” treatment failure as composites with definitive 
treatment failure. These were determined by a blinded endpoint committee 
according to the following criteria: 
 a) Loosening of a prosthesis, confirmed radiologically; or 
 b) Non-union of a fracture after 6 months, confirmed radiologically; or  
 c) Superficial spreading erythema, treated as cellulitis with an antibiotic 
for >1 week, where results from deep tissue samples did not meet the primary 
endpoint as described above. 
Where appropriate deep tissue samples were sent for microbiology and the 
results of culture were negative, and either a), b) or c) were met, the endpoint 
was regarded as “possible”. On the other hand, where deep tissue samples 
were not sent for microbiology, and either a), b) or c) were met, then the 
endpoint was regarded as “probable”; 
4) Early termination of the planned 6-week period of oral or IV antibiotics 
because of adverse events, patient preference or any other reason; 
5) Resource allocation determined by: a) length of inpatient hospital stay; b) 
frequency of outpatient visits and c) antibiotic prescribing costs; 
6) Quality of life evaluated by EQ-5D-3L questionnaire; 
7) Oxford Hip and Knee Scores (where infection was in the hip or knee); and 
8) Adherence to oral medication. 
The study clinicians determined secondary endpoints 1, 2, 4 and 5. The blinded 
endpoint review committee determined primary endpoints and secondary endpoint 3, 
by reviewing relevant clinical notes redacted for personal details and any information 
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which might have betrayed the treatment allocation. In cases where potential 
treatment failures did not fit clearly into either definite, probable, possible or no 
treatment failure, the blinded endpoint committee achieved consensus by discussion 
or, if necessary, by majority opinion. 
Participant questionnaires determined secondary endpoints 6 and 7. Secondary 
endpoint 8 was determined by questionnaire in all centres, and by MEMS at four 
sentinel sites. 
 
Choice of non-inferiority margin 
The choice of NI margin was discussed in detail at the time of trial design in terms of 
clinical relevance. There were few previous studies in this population which could 
reliably inform the choice but  10% non-inferiority margins have been recommended 
by licencing authorities for antibiotic trials1,2 and are commonly used in other 
infections with failure rates of the order of 10% (or equivalently success rates of 
90%).3,4  Based on this, and the fact that we anticipated failure rates with IV 
antibiotics to be small in absolute terms (5%), such that an absolute difference was 
more relevant than a relative difference, we and the co-investigators agreed, 
following discussion with a wide range of clinicians, infection specialists and 
orthopaedic surgeons that a 5% non-inferiority margin for the risk difference on the 
absolute scale was reasonable clinically. Although an absolute increase of 5% 
translated to a relative increase of 100%, this was deemed clinically acceptable 
considering the low absolute risk i.e. corresponding to a worst case scenario of the 
upper limit of the 90% confidence interval suggesting that failure rates might be 10% 
in the PO arm (5% control group + 5% NI margin), and the other benefits to patients 
and the healthcare system that the PO arm was expected to deliver. Such potential 
benefits included circumventing the need for intravenous access devices, reduced 
frequency of hospital follow-up appointments for therapeutic drug monitoring and line 
reviews, reduced reliance on community IV nurses and fewer restrictions in activities 
of daily living and attendance at work. In addition, we anticipated that participants in 
the PO arm would be able to leave hospitals earlier, thereby reducing the pressure 
on hospital beds and the demand on health resources through introduction of a cost-
saving intervention. 
  
The original control group failure rate (5%) was based on pilot data from a limited 
number of participants from one specialised centre. At a planned interim analysis in 
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February 2015 after 601 patients had been randomized across multiple sites, the 
observed event rate in the IV arm was approximately 12.5%, higher than the “worst 
case” scenario envisaged for the original 5% NI margin. It can be inappropriate to 
maintain the relative or absolute risk difference after an observed change in the 
underlying event rate in the control group.5 With this larger control group event rate, 
retaining the same 5% absolute non-inferiority margin would have corresponded to a 
much smaller relative difference (40% rather than 100%) which was considered too 
restrictive in light of the higher control group failure rate (meaning that more 
participants were already experiencing poor outcomes) and hence a slightly greater 
increase in the absolute percentage experiencing them on PO could be tolerated, 
given the potential benefits of PO therapy outlined above. The NI margin was 
therefore pragmatically amended to 7.5% on the absolute risk difference scale 
(corresponding to a 60% relative difference), being still more stringent than 
commonly used 10% margins in anti-infective trials, but only slightly larger than the 
original 5% absolute margin. This was based on its correspondence to a worst-case 
scenario of the upper limit of the 90% confidence interval suggesting that failure rates 
might be 20% in the PO arm (12.5% control group + 7.5% NI margin) compared to 
the original 10% (5% control group + 5% NI margin). By way of  example, the Federal 
Drug Authority (FDA) provides a worked example in its most recent November 2016 
guidance for antibiotic trials in community acquired bacterial pneumonia (CABP).2 
Historical observational studies estimated mortality rates of between 30-80% without 
antibiotics and 5-17% with antibiotics. Based on this, the FDA concluded that “Use of 
an NI margin of approximately 10% is therefore a valid approach for evaluating new 
treatments of CABP and would clearly represent an effect superior to no treatment as 
well as, based on clinical judgment, an appropriate clinical margin”. For the serious 
infections eligible for this trial, historical data  suggest that, without antibiotics,  
mortality would be between 5-25% and treatment failure rates likely >50%, compared 
to <20% with antibiotics.6  The FDA guidance would therefore have suggested that a 
margin of 10% could have been considered for this trial, had it been intended for 
licensing. Retaining the original 5% non-inferiority margin with the higher control 
group event rate (12.5% vs original 5%) and the same alpha/power would also have 
increased the sample size from 1050 to 1668; this was unfeasible given the funding 
constraints and effect on trial duration. The increase in non-inferiority margin to 7.5% 
was approved as a protocol amendment by the Trial Steering, Data Monitoring and 
the Ethics Committees. 
  12 
Statistical Analyses 
The primary endpoint for ITT, mITT, per-protocol and sensitivity analyses were 
reported with 90% confidence intervals (following the sample size calculation) and 
also with 95% confidence intervals. All secondary and sub-group analyses were 
reported with 95% confidence intervals.   
Subgroup analyses were based on the mITT population except for those concerning 
definite / probable / possible infection at baseline, which were performed in both the 
ITT and mITT populations. Odds ratios were obtained from logistic regression models 
using definitive treatment failure as the dependent variable, and randomized 
allocation, relevant subgroup and the interaction term as the only covariates. 
Imputation for the primary endpoint used chained estimating equations with data 
augmentation and included the following variables identified as relevant in predicting 
outcomes by the Chief Investigator before the final analysis: 
 Infection details at baseline were combined as follows and used as binary 
variables in the imputation model: 
o Chronic osteomyelitis debrided, no current implant or device OR spinal 
infection debrided 
o Chronic osteomyelitis as above, but not debrided OR spinal infection not 
debrided 
o Implant or device present and retained (“DAIR”) 
o Removal of orthopaedic device for infection OR prosthetic joint implant 
removed 
o Prosthetic joint implant, 1-stage revision 
 Whether or not antibiotic beads/ cement were used in the index operation 
 Participants’ comorbidity status (yes vs. no): 
o Diabetes 
o Peripheral vascular disease  
o Current smoker 
o Rheumatoid arthritis or systemic autoimmune disease 
 Staphylococcus aureus present in samples taken before randomisation 
 Pseudomonas species present in samples taken before randomisation 
 Age 
 Gender 
20 imputations were combined using Rubin’s rules. 
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Internal Pilot study 
Randomization started in one centre (Oxford) as a pilot centre to demonstrate 
feasibility of recruitment. Data from the pilot study were never analysed on their own, 
but only as part of the main trial analyses. 
 
Health economic analysis 
Full formal cost-effectiveness analysis was beyond the scope of this manuscript and 
will therefore be reported separately.  A summary of methods and results is 
presented here.  
 
A within trial analysis was based on the resource use and Health Related Quality of 
Life (EQ-5D-3L) data collected during the trial.  We considered the following cost 
categories: antibiotic costs, the costs of intravenous administration (including 
equipment and staff time) and inpatient stays through one year of follow-up.  The 
British National Formulary was used for antibiotic costs (with adjustment for hospital 
pharmacy discounts) and standard NHS reference costs were used for 
hospitalizations, equipment and staff resource.     
 
The total cost per participant in each intervention was summed and divided by the 
number of participants to calculate the mean cost per participant in each arm, along 
with the difference in means and 95% confidence interval.  All resources were valued 
in GBP (pounds sterling) at the time of analysis, using the Health Service Cost Index 
where necessary to adjust for price changes from year to year. 
 
The EQ-5D-3L instrument was used to estimate per-patient quality-adjusted life years 
(QALY) with adjustment for any differences between the groups in EQ-5D-3L at 
baseline.  Non-parametric bootstrapping techniques were employed to confirm the 
robustness of the statistical analysis of cost, QALY and cost-per-QALY.   
 
The mean QALY per participant for each arm was calculated by summing all 
participants’ QALYs and dividing by the number of participants.  The difference in the 
means along with 95% confidence intervals was calculated.  The incremental cost-
effectiveness ratio was calculated by dividing the difference in mean costs by the 
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difference in mean QALYs.  Uncertainty in cost-effectiveness was represented on the 
cost-effectiveness plane and as confidence intervals for cost-effectiveness ratios. 
 
Within trial non-surgical treatment costs relating to antibiotics,  administration of 
antimicrobials (including equipment and staff time) and hospitalized bed-days 
(including readmissions) through one year of follow-up were an estimated £2,740 
(~$3,480) less per patient in the PO arm (95%CI:£1,488, £3,992). There was a non-
significant difference in quality-adjusted life-years of -0.008 (95%CI:-0.045,+0.031) 
favoring PO (Table S12;Figure S5).    
 
As the results of the trial showed non-inferiority of PO therapy, we did not include 
post-randomization surgical costs and it was not considered necessary or useful to 
extrapolate the observed results beyond the clinical trial period in order to explore 
potential lifetime differences in cost-effectiveness. 
 
Bayesian analysis 
We performed supplementary analysis within a Bayesian framework to estimate the 
probability that PO was inferior to IV by different degrees.7  We used a Bayesian 
binomial regression model to estimate the risk difference (and 90% credible interval) 
for definitive treatment failure between the treatment arms (i.e. PO vs. IV) in the 
modified intention-to-treat population (without imputation). Following the pre-specified 
primary analysis of the OVIVA trial, this analysis was not adjusted for any patient 
characteristics. 
 
We ran the Bayesian model with both a neutral (uninformative / flat) prior, as well as 
with a sceptical (informative) prior to explore its effects on the model estimates. The 
uninformative prior was estimated by a normal distribution with a mean of 0 and a 
standard deviation (SD) of 100. The informative prior hypothesised a 10% risk 
difference in favour of the IV strategy: Normal (0.1, SD=0.025). This analysis was 
performed in Stata version 15 using the ’bayes: binreg’ command. 
 
For the two Bayesian binomial regression models using the neutral and sceptical 
priors, the probability that PO was inferior to IV was calculated for a range of 
thresholds which could be considered as varying non-inferiority margins. As reported 
in the main manuscript results, the probabilities of PO being 1%, 2% and 5% non-
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inferior to IV using the neutral prior were 12.7%, 5.5% and 0.1% respectively. Figure 
S6 below plots the probabilities for PO being inferior to IV for a range of non-
inferiority margins for Bayesian models using the neutral as well as the sceptical 
prior.  
 
Regardless of the prior used, the probability that PO is worse than IV by 5% or more 
approaches 0. This provides reassurance that, regardless of the change to the non-
inferiority margin, the trial robustly demonstrates non-inferiority of PO as compared to 
IV therapy, as assessed by definitive treatment failure at one year. 
 
Supplementary Figures 
 
 
Figure S1 : Forest plot of odds ratios (95% CI) for definitive treatment failure by 
trial site (PO/IV)  
A total of 26 sites contributed to recruitment with median (IQR) of 8(4-44) and range 1 to 512 
participants per center.  At sites not represented in this forest plot, there were no treatment 
failures in one or both arms of the trial so formal outcome comparison was not possible. 
 
Figures for The Nuffield Orthopaedic Centre include 228 patients recruited during a single 
center internal pilot study.      
   
(Failure/No failure) 
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Figure S2:  Forest plot of odds ratios (95% CI) for definitive treatment 
failure by subgroups (PO/IV)   
1. Pre-specified subgroup analysis by diagnostic certainty.  Definite, probable and possible infection at baseline were 
determined by predefined criteria or, where necessary, by consensus through a blinded independent review committee. 
2. Pre-specified subgroup analysis by baseline surgical procedure. Subgroups were as follows: (1) Osteomyelitis of 
axial or extra-axial skeleton debrided, no current implant or device; (2) Osteomyelitis as above, but not debrided; (3) Implant or device 
present and retained (i.e. “DAIR”); (4) Removal of prosthetic joint or fracture fixation device for infection; (5) Prosthetic joint implant, 
single-stage revision. 
3. Pre-specified subgroup analysis by infecting pathogen.  Other than Staphylococcus aureus, we did not systematically 
collect data to species level.  5 cases of S. lugdunensis were reported; all were included in the subgroup labelled Coagulase negative 
Staphylococci.  Of 186 cases of Staphylococcus aureus for which antimicrobial susceptibilities were available, MRSA was identified in 
19.(10.2%). Amongst 74 cases of Gram negative infection (other than Pseudomonas) where susceptibilities were available, 2 were 
extended spectrum beta-lactamase (ESBL) producers, and 35 represented species capable of expressing Amp C.  There were no 
treatment failures in the PO arm of the Pseudomonas species subgroup and therefore comparison was not possible.   
4. 4a and 4b. Pre-specified subgroup analyses by planned IV and PO treatment (excluding adjunctive oral 
rifampicin) as stated immediately prior to randomization. 
5. 5a and 5b. Pre-specified subgroup analyses by planned use of adjunctive oral rifampicin in the IV and 
PO arm as stated immediately prior to randomization.  
6. Post-hoc subgroup analysis by metal retained vs no metal retained.    Excludes vertebral osteomyelitis and 
participants managed without surgical debridement. Prosthetic material other than metal was not considered in this analysis. 
7. Post-hoc subgroup analysis by infecting pathogen known or unknown. 
8. Post-hoc subgroup analysis by peripheral vascular disease. 
9. Post-hoc subgroup analysis by use of adjunctive local antibiotic therapy. 
(Failure/No failure) 
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Figure S3: Kaplan-Meier curves for time to treatment failure by randomized 
strategy 
Hazard ratio  p=0.57  
 
 
 
Figure S4: Time from admission to discharge 
p<0.001 (Ranksum test for difference in median time to discharge)  
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Figure S5: Cost effectiveness plane showing 1000 bootstrap samples  
All fall in the Southern quadrants of the plane indicating that, in each case, PO antibiotic 
therapy cost less than IV therapy using data from the OVIVA trial.  Samples in the South 
East quadrant represent higher QALYs than those in the South West quadrant; the sample 
distribution suggests that there remains uncertainty as to whether QALYs clearly favor the 
oral or intravenous arm. 
 
 
 
 
Figure S6: Exploratory Bayesian analysis within the mITT population   
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Supplementary Tables 
Table S1a: Supplementary baseline information 
 IV Antibiotic 
(N = 527) 
PO Antibiotic 
(N = 527) 
Total 
(N = 1054) 
Clinical presentation*     
   - localised pain 397 (75.3%) 403 (76.5%) 800 (75.9%) 
   - localised erythema 226 (42.9%) 207 (39.3%) 433 (41.1%) 
   - temperature > 38.0 C 62 (11.8%) 62 (11.8%) 124 (11.8%) 
   - discharging sinus / wound 296 (56.2%) 285 (54.1%) 581 (55.1%) 
Anatomical site of infection*    
- spinal infectiona 37 (7.0%) 35 (6.6%) 72 (6.8%) 
- upper limb infection 43 (8.2%) 59 (11.2%) 102 (9.67%) 
- lower limb infectionb 436 (82.7%) 419 (79.5%) 855 (81.1%) 
- other area of infection 12 (2.3%) 14 (2.7%) 26 (2.5%) 
Operative details*    
   - draining sinus arising from 
bone / prosthesis 
177 (33.6%) 142 (26.9%) 319 (30.3%) 
   - frank pus adjacent to bone / 
prosthesis 
179 (34.0%) 186 (35.3%) 365 (34.6%) 
   - intraoperative local antibiotics 
(cement or beads) 
165 (31.3%) 179 (33.8%) 343 (32.5%) 
Baseline diagnosis 
determination* 
   
- clinical findingsc (with or without 
other findings) 
285/527 
(54.1%) 
273/527  
(51.8%) 
 558/1054 
(52.9%) 
- microbiological findingsd (with 
or without other findings) where 
microbiology samples were 
submitted 
402/500 
(80.4%) 
400/503  
(79.5%) 
802/1003 
(80.0%) 
- histological findingse (with or 
without other findings) where 
histology samples were 
submitted 
266/310 
(85.8%) 
277/326  
(85.0%) 
543/636  
(85.4%) 
Baseline diagnosis determination 
by mutually exclusive category*: 
   
- clinical and microbiological and 
histological findings 
144 (27.3%) 136 (25.8%) 280 (26.6%) 
- clinical and microbiological 
findings 
87 (16.5%) 91 (17.3%) 178 (16.9%) 
- clinical and histological findings 22 (4.2%) 20 (3.8%) 42 (4.0%) 
- microbiological and histological 
findings 
79 (15.0%) 91 (17.3%) 170 (16.1%) 
- clinical findings only 32 (6.1%) 26 (4.9%) 58 (5.5%) 
- microbiological findings only 92 (17.5%) 82 (15.6%) 174 (16.5%) 
- histological findings only 21 (4.0%) 30 (5.7%) 51 (4.8%) 
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- otherf 50 (9.5%) 51 (9.7%) 101 (9.6%) 
Comorbidities*     
- diabetes 107 (20.3%) 98 (18.6%) 205 (19.5%) 
- renal failure 11 (2.1%) 11 (2.1%) 22 (2.1%) 
- ischaemic heart disease 43 (8.2%) 45 (8.5%) 88 (8.4%) 
- peripheral vascular disease 31 (5.9%) 32 (6.1%) 63 (6.0%) 
- previous stroke or TIA 19 (3.6%) 22 (4.2%) 41 (3.9%) 
- dementia 1 (0.2%) 1 (0.2%) 2 (0.2%) 
- immunosuppressive medication 28 (5.3%) 17 (3.2%) 45 (4.3%) 
- known HIV infection 1 (0.2%) 3 (0.6%) 4 (0.4%) 
- rheumatoid arthritis or 
autoimmune disease 
47 (8.9%) 38 (7.2%) 85 (8.1%) 
- current smoker 61 (11.6%) 79 (15.0%) 140 (13.3%) 
- malignancy (current or 
diagnosed <2 years) 
17 (3.2%) 17 (3.2%) 34 (3.2%) 
* Frequency and percentages are displayed 
   
aThis figure includes spinal and pelvic osteomyelitis 
b Details of lower limb sites shown in table S1b 
c Defined by a draining sinus tract arising from bone/prosthesis and/or frank pus adjacent to 
bone/ prosthesis at operation 
d Defined by indistinguishable bacterial isolates from ≥ 2 deep tissue samples or a 
pathogenic organism from a single closed aspirate or biopsy 
e Defined by characteristic inflammatory infiltrate or microorganisms on microscopy 
f  For 101 participants who could not be classified by the responsible infection specialist as 
definite infection according predefined protocol definitions, baseline diagnostic categorization 
was determined by an independent blinded assessment committee according to a range of 
clinical criteria, including radiological findings:   8 of these participants were classified as 
definite infection, 23 as probable infection, and 51 as possible infection. A further 19 
participants had insufficient clinical information available to permit categorization according to 
predefined criteria but all were treated with antibiotics and were therefore included as 
possible infection at baseline 
 
 
Table S1b: Information on location of infection where lower limbs affected  
  IV Antibiotic  
(N = 436) 
PO Antibiotic 
(N = 419) 
Total 
(N = 855) 
Hip* 110 (25.2%) 104 (24.8%) 214 (25.0%) 
Knee* 133 (30.5%) 115 (27.5%) 248 (29.0%) 
Foot* 89 (20.4%) 86 (20.5%) 175 (20.5%) 
Other area of lower limb 
infection* 
105 (24.1%) 113 (27.0%) 218 (25.5%) 
*Frequency and percentages are displayed 
   
(Data on the location of infection in the lower limb were not available for four participants) 
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Table S2:  Criteria defining primary endpoints (definitive treatment failure) 
* Frequency and percentages are displayed 
 
a Defined by a draining sinus tract arising from bone/prosthesis and/or frank pus adjacent to 
bone/ prosthesis at operation 
b Defined by indistinguishable bacterial isolates from ≥ 2 deep tissue samples or a 
pathogenic organism from a single closed aspirate or biopsy 
c Defined by characteristic inflammatory infiltrate or microorganisms on microscopy 
 
  
 
IV Antibiotic 
(N = 74 ) 
PO Antibiotic 
(N = 67 ) 
Total 
(N = 141 ) 
Definite treatment failure 
determination* 
   
- clinical findingsa (with or without 
other findings) 
49 (66.2%) 34 (50.7%) 83 (58.9%) 
- microbiological findingsb (with 
or without other findings) where 
microbiology samples were 
submitted 
54 (73.0%) 47 (70.1%) 101 (71.6%) 
- histological findingsc (with or 
without other findings) where 
histology samples were 
submitted 
18 (24.3%) 11 (16.4%) 29 (20.6%) 
Definite treatment failure 
determination by mutually 
exclusive category*: 
   
- clinical and microbiological and 
histological findings 
6 (8.1%) 3 (4.5%) 9 (6.4%) 
- clinical and microbiological 
findings 
23 (31.1%) 13 (19.4%) 36 (25.5%) 
- clinical and histological findings 4 (4.5%) 1 (1.5%) 5 (3.6%) 
- microbiological and histological 
findings 
8 (10.8%) 5 (7.5%) 13 (9.2%) 
- clinical findings alone  16 (21.6%) 17 (25.4%) 33 (23.4%) 
- microbiological findings alone  17 (23.0%) 26 (38.8%) 43 (30.5%) 
- histological findings alone  0 (0.0%) 2 (3.0%) 2 (1.4%) 
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Table S3: Results of imputations for patients with missing data in the ITT 
analysis 
 IV Antibiotic 
(N = 527) 
PO Antibiotic 
(N = 527) 
Total 
(N = 1054) 
Participants without observed 
data for the primary endpoint 
21 (4.0%) 18 (3.4%) 39 (3.7%) 
Definitive treatment failures 
(out of all participants with 
observed primary endpoint 
data) 
74/506 
(14.6%) 
67/509 
(13.2%) 
141/1015 
(13.9%) 
Range of imputed numbers of 
definitive treatment failures out 
of those with missing data 
1 to 6 
(out of 21) 
0 to 7 
(out of 18) 
 
Range of % definitive 
treatment failures in the 
imputed datasets  
14.2% to 
15.2% 
12.7% to 
14.0% 
 
 
 
 
 
 
Table S4: Categorisation of endpoints as: ‘definite’ or 'probable' or 'possible'  
treatment failure (complete cases population – i.e. the mITT population) 
 
 
IV Antibiotic * 
(N = 506) 
PO Antibiotic * 
(N = 509) 
Total * 
(N = 1015) 
Any treatment failure* 80 (15.8%) 77 (15.1%) 157 (15.5%) 
 IV Antibiotic 
(N = 80) 
PO Antibiotic 
(N = 77) 
Total 
(N = 157) 
Endpoint category*    
    Definite treatment failure 74 (92.5%) 67 (87.0%) 141 (89.8%) 
    Probable treatment failure 5 (6.3%) 8 (10.4%) 13 (8.3%) 
    Possible treatment failure 1 (1.3%) 2 (2.6%) 3 (1.9%) 
 
* Frequency and percentages are displayed   
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Table S5: Patient reported outcome measures – treatment effects observed for 
EQ-5D-3L , OHS & OKS 
 Day 14 Day 42  Day 120  Day 365 
Treatment effect for 
the EQ-5D index 
PO vs. IV* 
-0.003 
(-0.052, 
0.046), 
P=0.92 
0.005 
(-0.057, 
0.066), 
P=0.88 
-0.032 
(-0.1, 0.035), 
P=0.35 
-0.014 
(-0.065, 
0.038), 
P=0.61 
N 596 631 554 533 
Treatment effect for 
the EQ-5D VAS 
PO vs. IV* 
0.206 
(-3.243, 
3.656), 
P=0.91 
2.069 
(-1.293, 
5.431), 
P=0.23 
-1.64 
(-6.082, 
2.801), 
P=0.47 
-1.527 
(-5.617, 
2.562), 
P=0.46 
N 571 610 533 514 
Treatment effect for 
the OHS 
PO vs. IV** 
Not 
measured 
Not 
measured 
-2.416 
(-8.503, 
3.672), 
P=0.43 
-4.199 
(-10.391, 
1.992), 
P=0.18 
N - - 137 109 
Treatment effect for 
the OKS 
PO vs. IV** 
Not 
measured 
Not 
measured 
5.766 
(1.168, 
10.364), 
P=0.01 
4.407 
0.366, 
10.449), 
P=0.04 
N - - 137 134 
*The quantile regression models were adjusted for baseline EQ-5D-3L index/ VAS, gender, 
age, diagnosis of diabetes mellitus, ischaemic heart disease, peripheral vascular disease, 
previous stroke or TIA, use of immunosuppressive medication, rheumatoid arthritis, current 
smoking status, baseline surgical procedure, and infecting pathogen. 
 
** The quantile regression models were adjusted for baseline OHS/ OKS, gender, age, 
diagnosis of diabetes mellitus, ischaemic heart disease, rheumatoid arthritis, current smoking 
status, baseline surgical procedure, and infecting pathogen. 
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Table S6: Self-reported adherence with antibiotics at day 14 & 42 using the 
Morisky Adherence Measure 8 (Maximum score is 8) 
 IV Antibiotic  
(N = 72†) 
PO Antibiotic 
(N = 303) 
Total 
(N = 375) 
Adherence score* (Day 14) 8 (8, 8), (5, 8) 8 (7, 8), (1, 8) 8 (8, 8), (1, 8) 
Adherence categoriesa 
(Day 14) 
   
    High adherence 49 (68.1%) 207 (68.3%) 256 (68.3%) 
    Medium adherence 20 (27.8%) 71 (23.4%) 91 (24.3%) 
    Low adherence 2 (2.8%) 18 (5.9%) 20 (5.3%) 
    Missingb 1 (1.4%) 7 (2.3%) 8 (2.1%) 
 IV Antibiotic 
(N = 80) 
PO Antibiotic 
(N = 323) 
Total 
(N = 403) 
Adherence score* (Day 42) 8 (7, 8), (4, 8) 8 (7, 8), (0, 8) 8 (7, 8), (0, 8) 
Adherence categoriesa 
(Day 42) 
   
    High adherence 54 (67.5%) 166 (51.4%) 220 (54.6%) 
    Medium adherence 21 (26.3%) 117 (36.2%) 138 (34.2%) 
    Low adherence 3 (3.6%) 25 (7.7%) 28 (7.0%) 
    Missingb 2 (2.5%) 15 (4.6%) 17 (4.2%) 
* 
Median, IQR and range are displayed  
a
 The 8 item Morisky Adherence scale is a self-report measure used as a screening tool to 
identify poorly adherent patients who are considered at risk of adherence related treatment 
failure.   High adherence is defined by a Morisky score of 8; medium adherence is defined by 
a score of 6 or 7; low adherence is defined by a score of <6.  
Frequencies (and percentages) are dispalyed. 
  
b
Adherence scores were considered  missing if not all eight questions were answered 
† 
For participants randomized to IV therapy, Morisky questionnaires were routinely requested 
only from patients who had been taught to self-administer their medication. Questionnaire 
returns were not required in cases where a healthcare professional was responsible for the 
administration of antibiotics.  
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Table S7: Compliance with PO antibiotics using Medication Event Monitoring 
System (MEMS) 9  
Compliance* (%) Frequency (N = 62^) Cumulative 
percentage (%) 
Total number 
of doses 
missed  
(N = 4060) 
100 32 51.6 0 
99 6 61.3 6 
98 11 79.0 15 
96 4 85.5 8 
95 3 90.3 9 
89 1 91.9 9 
86 1 93.5 12 
84 1 95.1 13 
82 1 96.7 10 
53 1 98.3 26 
45 1 100 46 
* Expressed as number of doses taken/number of doses anticipated (%) 
 
^ The MEMS subset included only consenting PO participants from four sentinel sites; it was 
not possible to subject IV therapy to MEMS technology 
 
 
 
Table S8: Summary of intended agents specified before randomization for use 
if patient was subsequently to be randomized to IV 
Intended IV agent Randomized to PO* 
(N = 411) 
Randomized to IV * 
(N = 506) 
Total * 
(N = 917) 
Glycopeptides 164 (39.9%) 216 (42.7%) 380 (41.4%) 
Penicillins 23 (5.6%) 16 (3.2%) 39 (4.3%) 
Cephalosporins 160 (38.9%) 185 (36.6%) 345 (37.6%) 
Carbapenems 26 (6.3%) 41 (8.1%) 67 (7.3%) 
Other single IV 
antibiotic 
22 (5.4%) 22 (4.3%) 44 (4.8%) 
^Combination IV 
antibiotics  
16 (3.9%) 26 (5.1%) 42 (4.6%) 
*Frequency and percentages are displayed   
 
^There were 9 different planned IV combination therapies in the IV arm, the commonest 
being teicoplanin + ceftriaxone (10 participants) and teicoplanin + ertapenem (6 participants) 
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Table S9: Summary of intended regimes (excluding rifampicin) specified before 
randomization for use if patient was subsequently to be randomized to PO 
*Frequency and percentages are displayed 
 
^There were 19 different planned oral combination regimens in the PO arm, the commonest 
being ciprofloxacin + clindamycin (19 participants) and ciprofloxacin + doxycycline (17 
participants); these figures do not take account of adjunctive rifampicin which was analysed 
separately.   
 
 
 
Table S10: Overview of actual antibiotics (excluding rifampicin), as defined by 
agents used for more than one week during the initial six-week treatment 
period 
 Participants 
randomized to 
IV Antibiotic*  
(N = 521) 
Participants 
randomized to 
PO Antibiotic* 
(N = 523) 
Total* 
(N = 1044) 
Glycopeptidesa (IV)  214 (41.1%) 22 (4.2%) 236 (22.6%) 
Penicillins (IV)  38 (7.3%) 11 (2.1%) 49 (4.7%) 
Cephalosporins (IV)  173 (33.2%) 8 (1.5%) 181 (17.3%) 
Carbapenems (IV)  41 (7.9%) 5 (1.0%) 46 (4.4%) 
Other single IV antibiotic  35 (6.7%) 2 (0.4%) 37 (3.5%) 
Combination IV antibiotics  35 (6.7%) 6 (1.1%) 41 (3.9%) 
Penicillins (PO)  8 (1.5%) 83 (15.9%) 91 (8.7%) 
Quinolonesb (PO)  33 (6.3%) 191 (36.5%) 224 (21.5%) 
Tetracyclinesc (PO)  4 (0.8%) 57 (10.9%) 61 (5.8%) 
Macrolides / Lincosamide d (PO)  10 (1.9%) 68 (13.0%) 78 (7.5%) 
Other single PO antibiotic (PO)  10 (1.9%) 54 (10.3%) 64 (6.1%) 
Combination PO antibiotics (PO)  13 (2.5%) 87 (16.6%) 100 (9.6%) 
The categories in this table were not mutually exclusive; 149 participants fell into more than 
one category and the data do not take account of adjunctive rifampicin which was analysed 
separately. 
*Frequency and percentages are displayed 
   
a 
Glycopeptides were either teicoplanin or vancomycin 
Intended PO agent Randomized to PO* 
(N = 507) 
Randomized to IV* 
(N = 438) 
Total * 
(N = 945) 
 
Penicillins 74 (14.6%) 57 (13.0%) 131 (13.9%) 
Quinolones 209 (41.2%) 205 (46.8%) 414 (43.8%) 
Tetracyclines 47 (9.3%) 37 (8.5%) 84 (8.9%) 
Macrolides / 
Lincosamide 
58 (11.4%) 50 (11.4%) 108 (11.4%) 
Other single PO 
antibiotic 
47 (9.3%) 28 (6.4%) 75 (7.9%) 
^Combination PO 
antibiotics 
72 (14.2%) 61 (14.0%) 133 (14.1%) 
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b 
Quinolones were ciprofloxacin in all but two cases, one each of moxifloxacin and 
levofloxacin. Of 191 participants in the oral arm who were prescribed quinolones, 160 
(83.8%) were also prescribed rifampicin at some point during the trial. 
c 
Doxycycline was the only tetracycline antibiotic prescribed. 
d Macrolides were clarithromycin (4 cases) and erythromycin (2 cases); clindamycin was the 
only lincosamide used.  
 
 
 
 
Table S11:  Actual rifampicin use in 1049 participants  
Observed 
rifampicin usea 
Randomized to IV 
Antibiotic* (N=523) 
Randomized to PO 
Antibiotic* (N=526) 
Total* 
(N=1049) 
No rifampicin use  310 (59.3%) 233 (44.3%) 543 (51.8%) 
<2 weeksb 21 (4.2%) 36 (6.8%) 57 (5.4%) 
2 to 6 weeksb 72 (13.8%) 92 (17.5%) 164 (15.6%) 
>6 weeksb 120 (22.9%) 165 (31.4%) 285 (27.2%) 
*Frequency and percentages are displayed 
 
a 
The most commonly prescribed doses of rifampicic were 300mg BD (388 prescriptions) and 
450mg BD (133 prescriptions).    
b Based on the longest continuous period of use. 
 
 
 
 
 
 
Table S12: Multiple imputation results for total non-surgical treatment costs 
and QALYs10,11 through 1 year of follow up 
Results Randomized 
to IV 
Antibiotic*  
Randomized 
to PO 
Antibiotic* 
Difference  95% CI 
Costs 
£13,274 
(£446) 
£10,534 
(£453) 
£2,740 
(£638) 
£1,488 to 
£3,992 
QALYs 
0.537  
(0.013) 
0.545  
(0.015) 
-0.008 
(0.019) 
-0.045 to 
0.031 
* Means and standard errors are displayed 
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